|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the M. D. Anderson Cancer Center, Houston,
TX; Johns Hopkins Institute, Baltimore, MD; Texas Oncology P.A.,
Austin, TX; Hôpital Pitié Salpetrière, Paris,
France; Leeds General Infirmary, Leeds, United Kingdom; Ohio State
University, Columbus; Millennium Pharmaceuticals, Cambridge, MA; Ilex
Oncology, San Antonio, TX; and Long Island Jewish Medical Center, New
Hyde Park, NY.
This study investigated the efficacy, safety, and clinical
benefit of alemtuzumab (Campath-1H) for patients with relapsed or
refractory B-cell chronic lymphocytic leukemia exposed to alkylating agents and having failed fludarabine therapy. Ninety-three patients received alemtuzumab in 21 centers worldwide, with the aim to obtain an
overall response rate of at least 20%. Dosage was increased gradually
(target 30 mg, 3 times weekly, for a maximum of 12 weeks). Infection
prophylaxis was mandatory, beginning on day 8, and continuing for a
minimum of 2 months after treatment. Responses were assessed at weeks
4, 8, and 12, and patients were followed for 34 months. Overall
objective response in the intent-to-treat population (n = 93) was
33% (CR 2%, PR 31%). Median time to response was 1.5 months (range,
0.4-3.7 months). Median time to progression was 4.7 months overall, 9.5 months for responders. At data cut-off, 27 patients (29%) were alive;
overall median survival was 16 months (95% CI: 11.8-21.9) and
32 months for responders. Nineteen responders survived more than 21 months. Clinical benefit was observed both in responders and in
patients with stable disease. The most common adverse events were
related to infusion, generally grade 1 or 2 in severity, occurring
mainly in the first week. Grade 3 or 4 infections were reported in 25 patients (26.9%). However, only 3 (9.7%) of 31 patients who responded
to alemtuzumab treatment developed grade 3 or 4 infections on the
study. Alemtuzumab induced significant responses in these patients with
clinical benefit in the majority and with acceptable toxicity in a
high-risk group.
(Blood. 2002;99:3554-3561) B-cell chronic lymphocytic leukemia (B-CLL) is the
most common adult leukemia occurring in the Western Hemisphere and
mainly affects the elderly.1 Although it may have a long
clinical course, with survival up to 20 years after diagnosis, once
disease progresses, death is almost inevitable. For patients in whom
fludarabine treatment has failed, the prognosis is poor, with only
approximately 40% surviving beyond 12 months (median survival, 8 months).2
Major response rates in over 20% of patients with refractory B-CLL
have been achieved with alkylating agents such as
chlorambucil,3 and purine analogs, such as
fludarabine4,5 or cladribine.6 Fludarabine is
the most effective single agent with response rates ranging between
19% and 71%. It is more successful as front-line therapy,7,8 and as a salvage therapy when the patients
have not been heavily pretreated.9-11 However, such
responses may be short, and B-CLL often becomes refractory to repeated
courses of treatment with the same drug.
Patients who respond to alkylating agents and relapse may fail to
respond to fludarabine, and some patients fail to respond to
fludarabine even as front-line therapy. Alternative therapy is needed
for such patients, preferably using agents with a mode of action that
does not overlap with previous chemotherapy. One such alternative is
the use of monoclonal antibodies.
Alemtuzumab is a humanized monoclonal antibody directed against CD52, a
cell surface protein expressed at high density on most normal and
malignant B and T lymphocytes12 but not on hematopoietic stem cells.13 Binding of alemtuzumab to CD52 on target
cells may cause cell death by 3 different mechanisms: complement
activation,14 antibody-dependent cellular
cytotoxicity,15,16 and apoptosis.17
Based on prior reports from small studies demonstrating that
alemtuzumab was an effective salvage therapy for patients in whom
fludarabine had failed,18 this study was implemented to confirm these encouraging results in a larger cohort of patients with
advanced B-CLL. These patients had all been treated previously with
alkylating agents and had documented failure to fludarabine therapy.
A prospective, noncomparative phase II trial was conducted at 21 study centers in the United States and Europe (see Appendix for
participating investigators and centers). The primary objective of the
study was to assess the overall response (OR) rate in patients with
B-CLL who had received an alkylating agent and in whom fludarabine treatment had failed, using the 1996 National Cancer Institute Working
Group (NCIWG) criteria.19
Secondary objectives were to assess the safety profile of alemtuzumab
and to evaluate clinical benefit in this heavily pretreated patient
population. The study was conducted in accordance with good clinical
practice, and all patients gave informed written consent before
commencing treatment.
Patients
Baseline staging studies were performed within 4 weeks of
registration. In addition to physical examination, including assessment of palpable spleen, and a complete blood count, World Health
Organization (WHO) performance status, bone marrow aspirate, and
trephine biopsies were carried out, as was full laboratory testing.
Disease characteristics at enrollment are summarized in Table
1. At baseline, 78 patients (84%) had
lymphocytosis. Previous therapy for B-CLL is recorded in Table 1. The
median number of prior treatments was 3 (range, 2-7). All patients had
received prior alkylating agent therapy (median duration of treatment,
11.5 months; range, 0.1-121 months), and all but one had failed
fludarabine according to the protocol. Forty-three patients (46%) had
received multiple fludarabine treatments; 30 patients (32%) were
treated twice, 5 patients (5%) treated 3 times, and 8 patients (9%)
treated 4 times.
Treatment and evaluation Alemtuzumab was diluted into 100 mL 0.9% saline and administered over a 2-hour period through an intravenous infusion line containing a 0.22-µm filter. In the first week the dose was 3 mg, increased to 10 mg, and then to 30 mg as soon as infusion-related reactions were tolerated. If any grade 3 or 4 infusion-related adverse events (AEs) occurred, the lower dose was continued daily until tolerated. Treatment was continued at 30 mg, 3 times a week, up to a maximum of 12 weeks. Premedication with 50 mg diphenhydramine and 650 mg acetaminophen, 30 minutes prior to infusion, was used initially until treatment was well tolerated. If a patient experienced hematologic toxicity or a grade 3 or 4 infection while on treatment, therapy was postponed until the problem was resolved. If postponement lasted longer than a week, treatment was resumed at the lowest dose. Prophylaxis against infection in the form of trimethoprim/sulfamethoxazole (1 tablet twice daily, 3 times a week) and famciclovir (250 mg twice daily), or equivalent, was administered, starting on day 8 of treatment, continuing throughout the course and for a minimum of 2 months after treatment was complete. If venous access was temporarily lost, alemtuzumab was administered subcutaneously in divided doses of no more than 1 mL. Patients were treated for a minimum of 4 weeks provided they did not experience any adverse effects that would preclude continuation in the study. During treatment, weekly procedures included physical examinations, toxicity assessments, and a complete blood count. At weeks 4 and 8, patients were also evaluated for continuation of therapy by additional testing, including WHO performance status, assessment of lymph nodes, liver, and spleen, and full laboratory parameters. At weeks 4 and 8, complete resolution of disease (even if platelet counts and hemoglobin had not completely normalized) or progression of disease indicated treatment should be discontinued, while improvement indicated treatment should be continued. No change in disease status at week 4 indicated treatment should be continued, but if there was still no change at week 8, treatment was discontinued. At the end of treatment, week 12, testing was carried out as for week 4. At the data cut-off point, 93 patients had completed treatment.Follow-up After completion of alemtuzumab therapy, patients with CR, PR, or stable disease (SD) were assessed monthly over 6 months for performance status, hematology and all infections, plus documentation of major medical events considered possibly related to alemtuzumab. Disease status evaluation included lymph node measurement, spleen and liver measurement, and flow cytometry in a central laboratory, every 2 months. After 6 months, assessments took place at 3-month intervals until alternative treatment or death. Patients with continuing AEs or abnormal laboratory tests related to alemtuzumab treatment were followed until resolution of these events. Patients developing progressive disease (PD) were followed for survival until alternative treatment or death.Patients who relapsed during follow-up were not re-entered into the study but were eligible for retreatment under a compassionate-use protocol where considered appropriate. Statistical analysis A response rate (RR) of 20% or higher, with a lower limit of the 95% CI of at least 10%, was considered to be meaningful evidence of efficacy in this patient population. Therefore, 75 patients were required to estimate the CI to within 10% of the RR. The intent-to-treat (ITT) population was defined as patients who had received at least one dose of alemtuzumab. The primary end point was the objective response rate (CR + PR) according to 1996 NCIWG criteria.19 According to these criteria, CR is defined as freedom from clinical disease for at least 2 months with a "normal" blood count (hemoglobin > 11g/L, neutrophils > 1.5 × 109/L, lymphocytes < 4 × 109/L, platelets > 100 × 109/L) without transfusion. No constitutional symptoms may be present, with no lymphadenopathy, no hepatosplenomegaly; and less than 30% small lymphocytes in the bone marrow with no nodules. PR is defined as at least a 50% reduction in the number of lymphocytes in the blood and least a 50% reduction in lymphadenopathy or hepatosplenomegaly (or both). At least one of the following should be maintained for at least 2 months: hemoglobin more than 11g/dL or 50% improvement, platelets more than 100 × 109/L, neutrophils greater than 1.5 × 109/L without transfusion. PD is defined as lymphadenopathy, peripheral lymphocyte count, or hepatosplenomegaly increased by 50% or more or histology showing a more aggressive picture. Any response not falling into these categories is defined as SD.Estimates of duration of response, time to disease progression, and survival were calculated using Kaplan-Meier methodology.20 Duration of response was measured from the date the patient first met NCIWG response criteria (confirmation required 2 months later) to the date of progression, alternative therapy, or death. Time to treatment failure was defined as the date from initial administration of alemtuzumab to the first date of objective measurement of disease progression or to alternative therapy or death. Survival was measured from the day of the first dose of alemtuzumab to death; deaths from all causes were included. An analysis of clinical benefit was also conducted as a secondary end point. Samples were reviewed at a central pathology unit and confirmed by an independent review panel.
Demographics Between April and October 1998, a total of 93 patients at 21 study sites were registered and treated, of whom 73 were male, 20 female; 86 were white and 7 were black. The median age was 66 years (range, 32-86 years). Seventy-one (76%) of the study participants had advanced disease (Rai stage III/IV).Median time from preceding therapy in all patients was 4.1 months (range, 0.7-33 months), in responders 2.9 months (range, 0.8-27.1 months), and in patients with CR 2.2 months (range, 2.0-2.4 months). Fludarabine had been the immediate preceding therapy in 57 patients (61%) either as a single agent or in combination with other cytotoxic agents (eg, cyclophosphamide, mitoxantrone, etoposide with or without prednisone). Twenty-nine patients (31%) had received fludarabine or cladribine in combination with other cytotoxic agents, almost always mitoxantrone or cyclophosphamide. Fifteen patients (16%) had been previously treated with the combination of fludarabine or cladribine and cyclophosphamide, regimens that are used for salvage of patients in whom fludarabine alone has failed. All 15 of these patients had failed the combination therapy by the protocol definition. Almost half the patients had never responded to any nucleoside analog-based regimen (45 of 93, 48%). Sixty-five patients (70%) completed treatment according to the protocol, including some patients who discontinued because of PD. Treatment took up to 16 weeks to complete in 2 patients (2%) who received subcutaneous alemtuzumab injections due to loss of venous access, and in a further 12 patients (13%) due to dose interruptions. In 4 cases (4%), dose interruption prolonged treatment to between 17 and 28 weeks. Treatment was prematurely discontinued in 28 patients, 3 (3%) of whom were nonevaluable due to termination in the first week of therapy, and were therefore considered failures. Response Thirty-one (33%) of the 93 patients responded to alemtuzumab therapy (Table 2), significantly exceeding the target of 20% (95% CI: 10%-30%). Although only 2 patients (2%) achieved a CR using NCIWG criteria, 6 additional patients (7%) had clearing of B-CLL from all sites, but had persistent anemia and/or thrombocytopenia. At the last on-treatment assessment of these 6 patients, anemia was grade 1 in 2 patients and grade 2 in 2 patients, and thrombocytopenia was grade 2 in 4 patients, grade 3 in 1 patient, and grade 4 in 1 patient. Grades 3 and 4 thrombocytopenia resolved completely during long-term follow-up.
Responses by disease status are shown in Table 1. Responses to alemtuzumab were seen in all prognostic subsets and were similar in patients who had failed treatment or had previously had a short response to fludarabine. Patients were less likely to respond if they had Rai stage IV disease or at least one lymph node more than 5 cm in diameter, or WHO performance status of 2. Seven patients (7%) had previously been treated with the anti-CD20 monoclonal antibody, rituximab, which resulted in 1 PR, 2 SD, and 4 PD; alemtuzumab treatment of this group produced 1 PR, 4 SD, and 2 PD. Advanced age did not preclude response; the patients who achieved CR were 68 and 71 years of age, and the median age of responding patients was 66 (range, 46-78 years). Overall median time to response was 1.5 months (range, 0.4-3.7 months); 1.8 months in the case of the 2 complete responders and 1.2 months in the case of the 29 partial responders. Median duration of response was 8.7 months (range, 2.5-22.6+ months). Median time to progression in the ITT population was 4.7 months (range, 0.2-23.6+ months, including patients who discontinued early without formal assessment of progression) and 9.5 months (range, 3-23.6+ months) for the responding subgroup, with 3 patients (3%) still in remission (response durations of 17+ to 22.6+ months) at last follow-up. The Kaplan-Meier plot of overall survival is shown in Figure
1. Twenty-seven (35%) of the 93 patients
were alive with a median follow-up of 29 months, 3 (3%) had been lost
to follow-up, and 63 (68%) had died. In the majority of cases
(n = 37), cause of death was a consequence of malignancy, with an
additional 2 deaths due to autoimmune hemolytic anemia or idiopathic
thrombocytopenia purpura. Death was due to, or complicated by,
infection in 17 cases. The remaining deaths were due to inanition,
cerebrovascular accident, respiratory distress, and pulmonary embolism,
with 3 patients lost to follow-up. Death occurred during the study or within 30 days after treatment in 9 patients, between days 30 and
180 after treatment in 19 patients, and more than 180 days after
treatment in 35 patients. Median survival was 16 months (95% CI:
11.8-21.9). Nineteen (61%) of 31 responders were still alive 21 to 30 months after alemtuzumab therapy, with median survival of 32 months.
Response in blood and bone marrow is shown in Table
3, demonstrating substantial disease
reduction at these sites. Peripheral blood data were supplemented by
flow cytometry in 90 patients at baseline showing that clonal
CD19+ lymphocytosis in 89 patients had rapidly reduced with
alemtuzumab therapy (Figure 2). Median
number of malignant lymphocytes in the peripheral blood fell from
33.6 × 103/µL at baseline to
0.003 × 103/µL at week 4, and
0.001 × 103/µL at weeks 8 and 12 (Figure 3).
Alemtuzumab also induced responses at other major disease sites. Of 66 patients with lymphadenopathy at enrollment 49 (74%) responded; 18 patients (27%) achieved CR and 31 patients (47%) achieved at least a
50% reduction in enlarged nodes. Responses by size of lymph node at
enrollment are shown in Table 4 and demonstrate a lower response rate in the largest lymph nodes. Of 31 patients with hepatomegaly at enrollment, at the last treatment of
alemtuzumab, hepatomegaly was completely resolved in 16 patients (52%)
and 7 patients (23%) had at least a 50% reduction. Of 46 patients
with splenomegaly, 54% had complete resolution, and an additional 28%
showed at least a 50% reduction in size of the palpable spleen.
At enrollment, 76 patients (82%) had various cytopenias (hemoglobin
Evidence of clinical benefit At the end of treatment, clinical benefit was also assessed (Table 5). Of the 31 responders, 17 had B-symptoms on entry, such as fever, night sweats, or weight loss, which resolved in all 17 cases. In total, 59 patients had B-symptoms or fatigue that resolved entirely in 31 patients (52.5%), including those with SD. In a selected group of patients with SD who were assessed for 6 categories of clinical benefit, the most common improvement was an increase in chemotherapy-free time; before alemtuzumab, the median was 3.8 months, and after alemtuzumab treatment, 7.6 months. The median chemotherapy-free periods prior to and following alemtuzumab treatment in the group of responders (n = 31) were 4.0 months and 12.4 months, respectively. Seventeen of the responders had chemotherapy-free periods of more than 1 year following alemtuzumab treatment. Other disease-related symptoms also resolved. In total, 42 (45%) of 93 patients survived more than 18 months, and 21 (68%) of 31 responders were still alive at the end of the study (Figure 1). Massive splenomegaly (> 6 cm) resolved in 90% of responders and 25% overall. In patients with anemia (NCIWG hemoglobin grades 1-4) at baseline, 73% of responders and 49% of patients overall experienced improvement in hemoglobin by at least one grade by follow-up.
Infusion-related toxicity In 75 (81%) of 93 patients, the complete duration of alemtuzumab administration, including dose delays and interruptions, occurred within 12 calendar weeks. In 14 patients (15%), between 13 and 16 calendar weeks were required to complete therapy, and in only 4 patients (4%) did this period exceed 16 weeks. Two patients had treatment postponed for approximately 3.5 months by the investigator. A median daily dose of 30 mg was achieved by 87 patients (93%), and the median cumulative dose (MCD) was 673 mg (range, 200-1106 mg), with 2 patients reaching an MCD of less than 200 mg, 18 reaching 200 to 399 mg, 16 reaching 400 to 599 mg, 24 reaching 800 to 999 mg, and 19 reaching 1000 to 1106 mg.The most commonly reported AEs were infusion related and were generally of grade 1 or 2 in severity. They included rigors (90% in total, 14% grade 3), fever (85% in total, 17% grade 3, 3% grade 4), nausea (53% in total, all grade 1 or 2), vomiting (38% in total, 1% grade 3) and rash (33% in total, all grade 1 or 2). Infusion-related toxicity decreased with time, and, except for rashes, there was a substantial decrease in incidence from week 1 to weeks 2 to 4, with a further decrease reported for treatment beyond week 4. Fewer than 0.5 events, per patient at risk (receiving infusions), were reported from week 2 until the end of the study. This decrease in the number of events over time on treatment was also apparent when only grade 3 or 4 acute infusion-related events were evaluated. During the study, 26 patients (28%) had dyspnea (11 patients, grade 3 or 4), 16 patients (17%) had hypotension (2 patients, grade 3 or 4) and 3 patients (3%) had hypoxia (2 patients, grade 3 or 4). Overall, 46 patients (49%) reported 65 episodes of serious AEs during the study, and in 49 of these reports, the primary event was considered to be related to alemtuzumab. Twenty-two patients (24%) discontinued because of AEs judged likely to be related to the treatment, the most common being infection (n = 8). The majority of these 22 patients had not responded to alemtuzumab. During long-term follow-up (median, 28 months), an additional 49 patients (53%), the majority of whom were nonresponders, died of complications attributable to disease, including disease progression (n = 26) and infection (n = 13). Of these 49 deaths, 30 occurred more than 6 months after treatment, and 4 were considered likely to be related to alemtuzumab treatment. Infectious complications A prior history of infection was reported in 49 (53%) of 93 patients, and 31 (33%) of 93 patients had an infection reported in the month prior to alemtuzumab administration, all mild except for 2 grade 3 infections. Overall, 51 patients (55%) experienced at least one infection during the study (Table 6). Infections were mild or moderate in 26 patients, and more severe (grade 3 or 4) in 25 patients. Septicemia occurred in 14 patients (15%). In 10 patients (10%), sepsis was grade 3 or 4, caused by gram-positive bacteria in 4 cases, Escherichia coli in 1 case, and Pseudomonas in 3 cases, with no causative organism identified in the other 2 cases. Two cases of sepsis led to death, on or within 30 days of study end. Superficial moniliasis occurred in 9 patients; and viral reactivation such as cytomegalovirus (CMV; n = 7) or Herpes simplex (n = 6) occurred in 13 patients. Significantly fewer patients who responded to alemtuzumab developed grade 3 or 4 infections during the study, 3 (10%) of 31 patients, compared with 22 of 62 nonresponding patients (36%, P < .01).
A total of 11 patients, all of whom had advanced disease, developed opportunistic infections (OIs) during treatment, some patients experiencing multiple OIs. A further 7 OIs occurred in the follow-up period. OIs included Pneumocystis carinii pneumonia (n = 1), no prophylaxis administered as per protocol; Aspergillus pneumonia (n = 1); rhinocerebral mucormycosis, a technically considered "on-study" fatal infection (n = 1); systemic candidiasis (n = 1); cryptococcal pneumonia (n = 1, fatal); Herpes zoster (n = 4 after study); pulmonary aspergillosis (n = 1 after study, fatal); invasive aspergillosis; and Listeria meningitis (n = 1, after study). The most commonly reported OI was CMV reactivation (n = 7), with 3 cases of grade 2 and 4 cases of grade 3 infection reported on study. There were no cases of CMV reported in the poststudy period. Five cases resolved and in 2 cases, CMV infection was the reason for treatment discontinuation. OIs were infrequently associated with concomitant use of systemic corticosteroids; of the cases above, 7 OIs occurred in patients who were treated with steroids for longer than 5 days. Patients who developed OIs were also, in general, heavily pretreated; 2 prior chemotherapy regimens had been used in only one case, while 3 regimens were previously used to treat 5 patients, and 12 patients had received between 4 and 7 prior regimens. Nine deaths occurred during treatment or within 30 days of the last administration of alemtuzumab. Three deaths were due to PD, 3 were due to pneumonia, and pulmonary embolism, sepsis, and rhinocerebral mucormycosis caused the remaining 3 deaths. Seven of these patients had advanced disease (Rai stage III or IV) at study entry, and all 9 had failed to respond to alemtuzumab. Five of the on-study deaths were caused by infection judged likely to be related to treatment. A further 19 deaths occurred between days 30 and 180, due to PD (n = 11), including one case of hemolytic anemia and one of idiopathic thrombocytopenia purpura), infection (n = 6), respiratory distress (n = 1), and inanition (n = 1). Cytopenias and immunosuppression Most patients experienced transient cytopenias during treatment. Neutropenia was most common during weeks 5 and 6 (30% patients) and resolved in the majority of patients by 2-month follow-up. Thrombocytopenia was most common during the first 2 weeks of therapy and by 2-month follow-up, recovery to or above baseline grade, was seen in 89% of patients' platelet counts and 85% of hemoglobin counts.Immunoglobulin A, G, and M shifts from baseline are shown in Table
7. No significant change was noted at any
level.
The median absolute CD3+/CD4+ T-cell count was lowest for the first assessment at week 4 (0.002 × 103/µL) but significantly increased (0.084 × 103/µL) by the assessment at week 12. Median CD4+ T-cell counts declined through week 4 and then began to rise (Figure 3). Similar results were observed for the CD3+/CD8+ T-cell count.
As treatment for B-CLL has evolved, patients treated with fludarabine have become more common, as has the number of patients having a relapse (progression within 6 months) or refractory to fludarabine treatment (fludarabine failed). This status is associated with a poor prognosis.2,21 In treating these patients with escalating doses of alemtuzumab, we observed a rapid OR rate of 33%, exceeding the expectations of 20% OR set at the start of the study, and also improved disease-related symptoms in patients with SD. A high proportion of patients achieved responses in the blood (83%) and bone marrow (26%). Responses were less common in Rai stage IV patients with low platelet counts, or patients of an advanced age. Although some patients with massive lymphadenopathy saw dramatic improvements in disease bulk, responses in bulky lymph nodes overall were less marked as has been previously observed with alemtuzumab therapy.22 Median time to progression for responders was 9.5 months, with 3 patients continuing in remission as of February 28, 2001. This study demonstrated a longer survival for all patients (median, 16 months) than other historical controls.2,21 Infusion-related toxicity such as rigors and fever became less common with time and remained below 0.5 events per patient at risk from week 2 until the end of the study. Some delays in treatment were necessary due to cytopenias and infections. Infections are already common in these patients, and it was anticipated that there would be a relatively high infection rate during treatment in this severely myelosuppressed patient population. The spectrum of infections was primarily bacterial, despite the T-cell depletion, which is a consequence of treatment. The incidence of OIs was lower than has been observed in other studies without trimethoprim/sulfamethoxazole and famciclovir prophylaxis. Famciclovir does not prevent CMV reactivation, which was the most common OI observed. No cases of grade 4 CMV infection were reported, and most lower-grade CMV infections responded rapidly to ganciclovir. Although, as expected, most of the patients had low baseline values for one or more of the immunoglobulin groups, shifts from baseline for IgG showed no significant changes. A total of 9 deaths occurred during treatment or within 30 days of last dose of alemtuzumab, of which 5, all associated with infections, were considered likely to be related to treatment. Early death rates and infectious death rates compare favorably to fludarabine pivotal studies, which reported an on-study death rate of 22% with half of these associated with infection.23 This study investigating patients with a poor prognosis indicates that there are some patients, namely those with bulky nodes or PS of 2, who are less likely to achieve a response following alemtuzumab therapy. Other salvage therapies that have been recently tested in refractory B-CLL include the combination of fludarabine and cyclophosphamide, which produced 38% response rates (3% CR) in patients refractory to fludarabine as a single agent,24 and rituximab, which achieved a 40% response rate (0% CR), in less heavily treated patients than reported in this study.25,26 This alemtuzumab study shows that patients who had failed treatment with rituximab were still able to respond to alemtuzumab. Future studies include the investigation of alemtuzumab in combination with other agents. Preliminary results indicate that the combination of alemtuzumab with fludarabine is effective in patients who are refractory to each agent alone, with 5 of 6 patients (83%) responding (4 PR, 1 CR).27 All patients had been heavily pretreated and in the 5 responders, bone marrow was cleared of morphologic evidence of B-CLL, including 3 cases that were negative by flow cytometry. These results should be followed up by larger scale studies. Current trials are also investigating the use of alemtuzumab in untreated patients using subcutaneous injection protocols and preliminary results in 23 evaluable patients show a high response rate (16 PR, 4 CR) with a good toxicity profile.28 More extensive studies may establish a role for alemtuzumab, alone or in combination, in previously untreated patients. In conclusion, alemtuzumab was effective and acceptably safe in a population of 93 high-risk patients with advanced B-CLL. Alemtuzumab was equally effective in patients who had failed purine analog therapy as in those who had never responded, and increased the median survival of these patients compared with historical controls. In addition, clinical benefit was shown in patients with SD as well as in those who responded, with improvements in hematologic parameters, reduction in bone marrow infiltration, and improvement in, or complete resolution of, disease-related symptoms.
Submitted August 23, 2001; accepted January 23, 2002.
Supported in part by research funding from Millennium Pharmaceuticals and ILEX Oncology. K.R.R. gratefully acknowledges a research grant from the Chemotherapy Foundation.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Michael J. Keating, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: mkeating{at}mdanderson.org.
1. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88:2398-2424[CrossRef][Medline] [Order article via Infotrieve]. 2. Keating M, O'Brien, S, Plunkett, W, et al. Results of first salvage therapy for patients refractory to a Fludara regimen in chronic lymphocytic leukemia. Leuk Lymphoma. In press. 3. Binet JL. Treatment of chronic lymphocytic leukaemia. French Co-operative Group on CLL. Baillieres Clin Haematol. 1993;6:867-878[CrossRef][Medline] [Order article via Infotrieve]. 4. Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol. 1988;30:457-459
5.
Keating MJ, O'Brien S, Lerner S, et al.
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Blood.
1998;92:1165-1171 6. Saven A. The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia. Semin Hematol. 1996;33:28-33[Medline] [Order article via Infotrieve]. 7. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996;347:1432-1438[Medline] [Order article via Infotrieve].
8.
Rai KR, Peterson BS, Appelbaum FR, et al.
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
N Engl J Med.
2000;343:1750-1757
9.
Gillis S, Dann EJ, Cass Y, Rochlemer RR, Polliack A.
Activity of fludarabine in refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma 10. Gjedde SB, Hansen MM. Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia. Leuk Lymphoma. 1996;21:317-320[Medline] [Order article via Infotrieve].
11.
Stelitano C, Morabito F, Kropp MG, et al.
Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
Haematologica.
1999;84:317-323
12.
Treumann A, Lifely MR, Schneider P, Ferguson MA.
Primary structure of CD52.
J Biol Chem.
1995;270:6088-6099
13.
Gilleece MH, Dexter TM.
Effect of Campath-1H antibody on human hematopoietic progenitors in vitro.
Blood.
1993;82:807-812 14. Heit W, Bunjes D, Wiesneth M, et al. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol. 1986;64:479-486[Medline] [Order article via Infotrieve].
15.
Dyer MJ, Hale G, Hayhoe FG, Waldmann H.
Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
Blood.
1989;73:1431-1439 16. Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol. 1993;23:1098-1104[Medline] [Order article via Infotrieve]. 17. Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology. 1998;95:427-436[CrossRef][Medline] [Order article via Infotrieve]. 18. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15:1567-1574[Abstract].
19.
Cheson BD, Bennett JM, Grever M, et al.
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
Blood.
1996;87:4990-4997 20. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457[CrossRef]. 21. Giles FJ, O'Brien SM, Santini V, et al. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma. 1999;36:57-65[Medline] [Order article via Infotrieve]. 22. Hoffman M, Jansen D, Rai, K. Analysis of response to Campath-1H in patients with B-CLL progressing after fludarabine therapy. IWCLL. 1999;Abstract P129. 23. Fludara Package Insert. Physician's Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Company; 1999:724-726.
24.
O'Brien SM, Kantarjian HM, Cortes J, et al.
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
J Clin Oncol.
2001;19:1414-1420
25.
O'Brien SM, Kantarjian H, Thomas DA, et al.
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
J Clin Oncol.
2001;19:2165-2170
26.
Byrd JC, Murphy T, Howard RS, et al.
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
J Clin Oncol.
2001;19:2153-2164
27.
Kennedy B, Rawstron AC, Carter C, Ryan M, Speed K, Lucas G, Hillmen P.
Campath-1H and fludarabine in combination is highly active in refractory CLL.
Blood.
2002;99:2245-2247 28. Lundin J, Björkholm M, Celsing F, et al. CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). Ann Oncol. 2000;11:96(abstract 4290).
Principal investigators and participating centers were J-L. Binet, Hôpital Pitié Salpetrière, Paris, France; R. B. Bolin, Bay Area Hospital, Coos Bay, OR; J. C. Byrd, Walter Reed Army Medical Center, Washington, DC; B. Cazin, Hôpital Claude Huriez, Lille, France; V. Diehl, Klink I für Innere Med Universistat, Koln, Germany; M. Divine, Hôpital Henri Monder, Créteil, France; M. J. S. Dyer, The Royal Marsden Hospital, Surrey, United Kingdom; C. Emmanouilides, UCLA, Los Angeles (one patient was enrolled but not treated at this site); I. W. Flinn, Johns Hopkins Institute, Baltimore, MD; P. Hillmen, Leeds General Infirmary, Leeds, United Kingdom; R. M. Hutchinson, Leicester Royal Infirmary, Leicester, United Kingdom; V. Jain, PRN, Dallas, TX; S. Johnson, Taunton & Somerset Hospital, Musgrove Park, Taunton, United Kingdom; M. J. Keating, M. D. Anderson Cancer Center, Houston, TX; M. Leporrier, Centre Hospitalier Universitaire, Caen, France; M. Milder, Swedish Medical Center, Seattle, WA; K. R. Rai, Long Island Jewish Medical Center, New Hyde Park, NY; A. Saven, Scripps Clinic, La Jolla, CA; B. Silver, University Hospitals of Cleveland, Cleveland, OH; P. Travade, Hôpital de l'Hotel Dieu, Clermont-Ferrand, France; D. Winfield, Royal Hallamshire Hospital, Sheffield, United Kingdom; L. Zehngebot, Walt Disney Cancer Center, Orlando, FL. An independent international panel of experts who had not participated in the study reviewed the key eligibility criteria and data related to disease response for all patients entered in this study. The following members of the panel are gratefully acknowledged: John M. Bennett, University of Rochester, Rochester, NY; Martin S. Tallman, Northwestern University, Chicago, IL; and Federico Caligaris-Cappio, University of Torino, Torino, Italy.
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. O'Brien, J. O. Moore, T. E. Boyd, L. M. Larratt, A. B. Skotnicki, B. Koziner, A. A. Chanan-Khan, J. F. Seymour, J. Gribben, L. M. Itri, et al. 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen J. Clin. Oncol., November 1, 2009; 27(31): 5208 - 5212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Delgado, D. W. Milligan, and P. Dreger Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time? Blood, September 24, 2009; 114(13): 2581 - 2588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Zenz, S. Habe, T. Denzel, J. Mohr, D. Winkler, A. Buhler, A. Sarno, S. Groner, D. Mertens, R. Busch, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial Blood, September 24, 2009; 114(13): 2589 - 2597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Stilgenbauer, T. Zenz, D. Winkler, A. Buhler, R. F. Schlenk, S. Groner, R. Busch, M. Hensel, U. Duhrsen, J. Finke, et al. Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group J. Clin. Oncol., August 20, 2009; 27(24): 3994 - 4001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Phelps, T. S. Lin, A. J. Johnson, E. Hurh, D. M. Rozewski, K. L. Farley, D. Wu, K. A. Blum, B. Fischer, S. M. Mitchell, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia Blood, March 19, 2009; 113(12): 2637 - 2645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Kim, K. Kim, B. S. Kim, C. Suh, J. Huh, Y. H. Ko, and W. S. Kim Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study Ann. Onc., February 1, 2009; 20(2): 390 - 392. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Elter, J. Kilp, P. Borchmann, H. Schulz, M. Hallek, and A. Engert Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia Haematologica, January 1, 2009; 94(1): 150 - 152. [Full Text] [PDF]
|
|
|
|
 |
|
 C Agostinelli, P P Piccaluga, P Went, M Rossi, A Gazzola, S Righi, T Sista, C Campidelli, P L Zinzani, B Falini, et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies J. Clin. Pathol., November 1, 2008; 61(11): 1160 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Sorror, B. E. Storer, B. M. Sandmaier, M. Maris, J. Shizuru, R. Maziarz, E. Agura, T. R. Chauncey, M. A. Pulsipher, P. A. McSweeney, et al. Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning J. Clin. Oncol., October 20, 2008; 26(30): 4912 - 4920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tan, S. Yang, J. Cai, J. Guo, L. Huang, Z. Wu, J. Chen, and L. Liao Simultaneous Islet and Kidney Transplantation in Seven Patients With Type 1 Diabetes and End-Stage Renal Disease Using a Glucocorticoid-Free Immunosuppressive Regimen With Alemtuzumab Induction Diabetes, October 1, 2008; 57(10): 2666 - 2671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Cheson and J. P. Leonard Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma N. Engl. J. Med., August 7, 2008; 359(6): 613 - 626. [Full Text] [PDF]
|
|
|
|
|
|
A. Ferrajoli, B.-N. Lee, E. J. Schlette, S. M. O'Brien, H. Gao, S. Wen, W. G. Wierda, Z. Estrov, S. Faderl, E. N. Cohen, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia Blood, June 1, 2008; 111(11): 5291 - 5297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Oldham and R. O. Dillman Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress J. Clin. Oncol., April 10, 2008; 26(11): 1774 - 1777. [Full Text] [PDF]
|
|
|
|
|
|
S. O'Brien, F. Ravandi, T. Riehl, W. Wierda, X. Huang, J. Tarrand, B. O'Neal, H. Kantarjian, and M. Keating Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy Blood, February 15, 2008; 111(4): 1816 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lapalombella, X. Zhao, G. Triantafillou, B. Yu, Y. Jin, G. Lozanski, C. Cheney, N. Heerema, D. Jarjoura, A. Lehman, et al. A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents Clin. Cancer Res., January 15, 2008; 14(2): 569 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Wierda Treatments for Patients with Chronic Lymphocytic Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 297 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Hillmen, A. B. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska, J. Wu, C. Sirard, and J. Mayer Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia J. Clin. Oncol., December 10, 2007; 25(35): 5616 - 5623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Flynn and J. C. Byrd Have We Forgotten the Purpose of Phase III Studies? J. Clin. Oncol., December 10, 2007; 25(35): 5553 - 5555. [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Dearden Role of antibody therapy in lymphoid malignancies Br. Med. Bull., September 1, 2007; 83(1): 275 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Byrd, S. O'Brien, I. W. Flinn, T. J. Kipps, M. Weiss, K. Rai, T. S. Lin, J. Woodworth, D. Wynne, J. Reid, et al. Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia Clin. Cancer Res., August 1, 2007; 13(15): 4448 - 4455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hosen, C. Y. Park, N. Tatsumi, Y. Oji, H. Sugiyama, M. Gramatzki, A. M. Krensky, and I. L. Weissman CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia PNAS, June 26, 2007; 104(26): 11008 - 11013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Bernengo, P. Quaglino, A. Comessatti, M. Ortoncelli, M. Novelli, F. Lisa, and M. T. Fierro Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients Haematologica, June 1, 2007; 92(6): 784 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Byrd, T. S. Lin, J. T. Dalton, D. Wu, M. A. Phelps, B. Fischer, M. Moran, K. A. Blum, B. Rovin, M. Brooker-McEldowney, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia Blood, January 15, 2007; 109(2): 399 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Morrison Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia Hematology, January 1, 2007; 2007(1): 332 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Venugopal and S. A. Gregory Lymphoproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 265 - 297. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Rodig, J. S. Abramson, G. S. Pinkus, S. P. Treon, D. M. Dorfman, H. Y. Dong, M. A. Shipp, and J. L. Kutok Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H) Clin. Cancer Res., December 1, 2006; 12(23): 7174 - 7179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stein, Z. Qu, S. Chen, D. Solis, H. J. Hansen, and D. M. Goldenberg Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab Blood, October 15, 2006; 108(8): 2736 - 2744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. L. Yee and S. M. O'Brien Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., August 1, 2006; 81(8): 1105 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sandherr, H. Einsele, H. Hebart, C. Kahl, W. Kern, M. Kiehl, G. Massenkeil, O. Penack, X. Schiel, S. Schuettrumpf, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO) Ann. Onc., July 1, 2006; 17(7): 1051 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Montillo, A. Tedeschi, S. Miqueleiz, S. Veronese, R. Cairoli, L. Intropido, F. Ricci, A. Colosimo, B. Scarpati, M. Montagna, et al. Alemtuzumab As Consolidation After a Response to Fludarabine Is Effective in Purging Residual Disease in Patients With Chronic Lymphocytic Leukemia J. Clin. Oncol., May 20, 2006; 24(15): 2337 - 2342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Montserrat, C. Moreno, J. Esteve, A. Urbano-Ispizua, E. Gine, and F. Bosch How I treat refractory CLL Blood, February 15, 2006; 107(4): 1276 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Delgado, K. Thomson, N. Russell, J. Ewing, W. Stewart, G. Cook, S. Devereux, R. Lovell, R. Chopra, D. I. Marks, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study Blood, February 15, 2006; 107(4): 1724 - 1730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Wierda Current and Investigational Therapies for Patients with CLL Hematology, January 1, 2006; 2006(1): 285 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Egyed, B. Kollar, E. Karadi, G. Rumi, and L. Kereskai A Case Study of a Patient with Chemotherapy Resistant CLL Successfully Retreated with Alemtuzumab. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 5037 - 5037. [Abstract]
|
|
|
|
|
|
T. Elter, P. Borchmann, H. Schulz, M. Reiser, S. Trelle, R. Schnell, M. Jensen, P. Staib, T. Schinkothe, H. Stutzer, et al. Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial J. Clin. Oncol., October 1, 2005; 23(28): 7024 - 7031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Wong Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities Clin. Cancer Res., October 1, 2005; 11(19): 7151s - 7157s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Waldmann and G. Hale CAMPATH: from concept to clinic Phil Trans R Soc B, September 29, 2005; 360(1461): 1707 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Wierda, T. J. Kipps, and M. J. Keating Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6325 - 6332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Z. Pavletic, I. F. Khouri, M. Haagenson, R. J. King, P. J. Bierman, M. R. Bishop, M. Carston, S. Giralt, A. Molina, E. A. Copelan, et al. Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research J. Clin. Oncol., August 20, 2005; 23(24): 5788 - 5794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Lin, M. R. Grever, and J. C. Byrd Changing the Way We Think About Chronic Lymphocytic Leukemia J. Clin. Oncol., June 20, 2005; 23(18): 4009 - 4012. [Full Text] [PDF]
|
|
|
|
|
|
W. Wierda, S. O'Brien, S. Wen, S. Faderl, G. Garcia-Manero, D. Thomas, K.-A. Do, J. Cortes, C. Koller, M. Beran, et al. Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia J. Clin. Oncol., June 20, 2005; 23(18): 4070 - 4078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Sorror, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. J. Stuart, U. Hegenbart, E. Agura, T. R. Chauncey, J. Leis, M. Pulsipher, et al. Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia J. Clin. Oncol., June 1, 2005; 23(16): 3819 - 3829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Byrd, B. L. Peterson, J. Gabrilove, O. M. Odenike, M. R. Grever, K. Rai, R. A. Larson, and the Cancer and Leukemia Group B Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805 Clin. Cancer Res., June 1, 2005; 11(11): 4176 - 4181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Moreton, B. Kennedy, G. Lucas, M. Leach, S. M.B. Rassam, A. Haynes, J. Tighe, D. Oscier, C. Fegan, A. Rawstron, et al. Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival J. Clin. Oncol., May 1, 2005; 23(13): 2971 - 2979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Shanafelt, Y. K. Lee, N. D. Bone, A. K. Strege, V. L. Narayanan, E. A. Sausville, S. M. Geyer, S. H. Kaufmann, and N. E. Kay Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine Blood, March 1, 2005; 105(5): 2099 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hallek and On Behalf Of The German CLL Study Group Chronic Lymphocytic Leukemia (CLL): First-Line Treatment Hematology, January 1, 2005; 2005(1): 285 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Gribben Salvage Therapy for CLL and the Role of Stem Cell Transplantation Hematology, January 1, 2005; 2005(1): 292 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Lin, I. W. Flinn, R. Modali, T. A. Lehman, J. Webb, S. Waymer, M. E. Moran, M. S. Lucas, S. S. Farag, and J. C. Byrd FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia Blood, January 1, 2005; 105(1): 289 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Christiansen and A. K. Rajasekaran Biological impediments to monoclonal antibody-based cancer immunotherapy Mol. Cancer Ther., November 1, 2004; 3(11): 1493 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Cheson What Is New in Lymphoma? CA Cancer J Clin, September 1, 2004; 54(5): 260 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hale, P. Rebello, L. R. Brettman, C. Fegan, B. Kennedy, E. Kimby, M. Leach, J. Lundin, H. Mellstedt, P. Moreton, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration Blood, August 15, 2004; 104(4): 948 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Lenihan, A. J. Alencar, D. Yang, R. Kurzrock, M. J. Keating, and M. Duvic Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome Blood, August 1, 2004; 104(3): 655 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Hong, J. Yan, J. T. Baran, D. J. Allendorf, R. D. Hansen, G. R. Ostroff, P. X. Xing, N.-K. V. Cheung, and G. D. Ross Mechanism by Which Orally Administered {beta}-1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models J. Immunol., July 15, 2004; 173(2): 797 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Olszewski and M. L. Grossbard Empowering Targeted Therapy: Lessons from Rituximab Sci. Signal., July 13, 2004; 2004(241): pe30 - pe30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lozanski, N. A. Heerema, I. W. Flinn, L. Smith, J. Harbison, J. Webb, M. Moran, M. Lucas, T. Lin, M. L. Hackbarth, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions Blood, May 1, 2004; 103(9): 3278 - 3281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stein, Z. Qu, S. Chen, A. Rosario, V. Shi, M. Hayes, I. D. Horak, H. J. Hansen, and D. M. Goldenberg Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma Clin. Cancer Res., April 15, 2004; 10(8): 2868 - 2878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Enblad, H. Hagberg, M. Erlanson, J. Lundin, A. P. MacDonald, R. Repp, J. Schetelig, G. Seipelt, and A. Osterborg A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas Blood, April 15, 2004; 103(8): 2920 - 2924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dreger, S. Stilgenbauer, A. Benner, M. Ritgen, A. Krober, M. Kneba, N. Schmitz, and H. Dohner The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status Blood, April 1, 2004; 103(7): 2850 - 2858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Rawstron, B. Kennedy, P. Moreton, A. J. Dickinson, M. J. Cullen, S. J. Richards, A. S. Jack, and P. Hillmen Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia Blood, March 15, 2004; 103(6): 2027 - 2031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Basquiera, A. R. Berretta, J. J. Garcia, and E. D. Palazzo Coronary ischemia related to alemtuzumab therapy Ann. Onc., March 1, 2004; 15(3): 539 - 540. [Full Text] [PDF]
|
|
|
|
|
|
T. D. Shanafelt and T. G. Call Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia Mayo Clin. Proc., March 1, 2004; 79(3): 388 - 398. [Abstract] [PDF]
|
|
|
|
|
|
J. C. Byrd, S. Stilgenbauer, and I. W. Flinn Chronic Lymphocytic Leukemia Hematology, January 1, 2004; 2004(1): 163 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Ghobrial, L. A. Otteman, W. L. White, D. A. Rizzieri, S. Weitman, and D. M. Vaughn An EBV-Positive Lymphoproliferative Disorder after Therapy with Alemtuzumab N. Engl. J. Med., December 25, 2003; 349(26): 2570 - 2572. [Full Text] [PDF]
|
|
|
|
|
|
M. Coleman, D. M. Goldenberg, A. B. Siegel, J. C. Ketas, M. Ashe, J. M. Fiore, and J. P. Leonard Epratuzumab: Targeting B-Cell Malignancies through CD22 Clin. Cancer Res., September 1, 2003; 9(10): 3991s - 3994s. [Abstract] [Full Text]
|
|
|
|
|
|
W. J. M. Mackus, F. N. J. Frakking, A. Grummels, L. E. Gamadia, G. J. de Bree, D. Hamann, R. A. W. van Lier, and M. H. J. van Oers Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia Blood, August 1, 2003; 102(3): 1057 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kumar, T. K. Kimlinger, J. A. Lust, K. Donovan, and T. E. Witzig Expression of CD52 on plasma cells in plasma cell proliferative disorders Blood, August 1, 2003; 102(3): 1075 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lundin, H. Hagberg, R. Repp, E. Cavallin-Stahl, S. Freden, G. Juliusson, E. Rosenblad, G. Tjonnfjord, T. Wiklund, and A. Osterborg Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome Blood, June 1, 2003; 101(11): 4267 - 4272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Byrd, D. M. Lucas, A. P. Mone, J. B. Kitner, J. J. Drabick, and M. R. Grever KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis Blood, June 1, 2003; 101(11): 4547 - 4550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Mavromatis and B. D. Cheson Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia J. Clin. Oncol., May 1, 2003; 21(9): 1874 - 1881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Faderl, D. A. Thomas, S. O'Brien, G. Garcia-Manero, H. M. Kantarjian, F. J. Giles, C. Koller, A. Ferrajoli, S. Verstovsek, B. Pro, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies Blood, May 1, 2003; 101(9): 3413 - 3415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Weiss, P. G. Maslak, J. G. Jurcic, D. A. Scheinberg, T. B. Aliff, N. Lamanna, S. R. Frankel, S. E. Kossman, and D. Horgan Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia J. Clin. Oncol., April 1, 2003; 21(7): 1278 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Herbert, H. M. Prince, and D. A. Westerman Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab Blood, February 15, 2003; 101(4): 1654 - 1654. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps Biology and Treatment of Chronic Lymphocytic Leukemia Hematology, January 1, 2003; 2003(1): 153 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. O'Brien, N. M.A. Blijlevens, T. H. Mahfouz, and E. J. Anaissie Infections in Patients with Hematological Cancer: Recent Developments Hematology, January 1, 2003; 2003(1): 438 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Rai, C. E. Freter, R. J. Mercier, M. R. Cooper, B. S. Mitchell, E. A. Stadtmauer, P. Santabarbara, B. Wacker, and L. Brettman Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine J. Clin. Oncol., September 15, 2002; 20(18): 3891 - 3897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Stilgenbauer and H. Dohner Campath-1H-Induced Complete Remission of Chronic Lymphocytic Leukemia despite p53 Gene Mutation and Resistance to Chemotherapy N. Engl. J. Med., August 8, 2002; 347(6): 452 - 453. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
11g/dL, absolute neutrophil count (ANC) < 1500, platelet count 
-the Jerusalem experience.
Leuk Lymphoma.
1994;15:173-175